Dynavax looking for Plan B for Heplisav-B

Dynavax Technologies Corp. (NASDAQ:DVAX) fell $7.50 (65%) to $4.10 on Monday after it received a complete response letter from FDA for the biotech’s Heplisav-B HBV vaccine and said it now wants a partner to help keep the program going.

In September, Dynavax said FDA expected to reach a decision on the BLA by its Dec. 15 PDUFA date (see BioCentury Extra, Sept. 6)...